Sutimlimab-jome is another of the monoclonal antibodies expressed by recombinant in CHO cells to be fda approved in 2022!
Developed by Bioverativ, a Sanofi company and commercialized under the name of Enjaymo, it is a classical complement inhibitor indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD)*
The role of CHOcells in drugdiscovery , drugdevelopment and drugmanufacturing is growing very fast, offering access to more and more patients to new and more efficient therapies
In this case, Enjaymo addresses a serious and chronic unmet medical need for adults living with CAD, a rare blood disorder and it has received FDA breakthrough therapy and orphandrugs designation after a priority review
Are you involved in R&D on antibodies ?
Are you planning to screen different protein variants?
We at Magellan Biologics & Consulting proudly support the scientificcommunity in their R&D projects through our CHO4Tx® product portfolio that allows in-house, fast, easy and efficient transient proteinexpression in CHO cells and through personalized advices and consultancies.
